Journal of Prostate Cancer
Open Access

Degarelix

Search results for
Degarelix

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Degarelix

Degarelix injection is used to treat advanced prostate cancer. Degarelix injection is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone produced by the body. This may slow or stop the spread of prostate cancer cells that need testosterone to grow.

Sexual effect: most of the men lose their sex drive and face problems in erection Skin rashes: mild skin rashes will develop. Weight gain: weight of person will increase

Related Journals of Degarelix

Journal of Prostate Cancer, Journal of Cancer Science & Therapy

Degarelix

Conference Proceedings